Compare Amgen, Inc. (AMGN) vs Lam Research Corporation (LRCX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amgen, Inc. vs Lam Research Corporation — how do they compare? Amgen, Inc. trades at $355.98 (market cap $196.12B), while Lam Research Corporation trades at $334.85 (market cap $438.11B). The key difference: Lam Research Corporation is far larger — about 2.2× Amgen, Inc.'s market cap, and Amgen, Inc. pays the higher dividend (2.77%). Which is the better fit depends on your goals.
| AMGN | LRCX | |
|---|---|---|
Market Cap | $196.12B | $438.11B |
Sector | Health | Technology |
52-Week High | $388.16 | $433.33 |
52-Week Low | $271.18 | $94.84 |
Enterprise Value | $241.41B | $437.10B |
Dividend Yield | 2.77% | 0.3% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
Lam Research (LRCX) trades at $350.33, down 0.8% on the day, with a neutral technical signal and bullish moving averages. The stock shows strong fundamentals with revenue growth to $18.44B in 2025 and net income of $5.36B, supported by consistent earnings beats. Recent news highlights AI-driven demand for semiconductor equipment, though valuation ratios like a P/E of 66.22 raise concerns about premium pricing.
Outlook remains positive with a consensus price target of $393, representing 12% upside, driven by AI infrastructure spending. Risks include high valuation sensitivity and semiconductor cycle volatility. Analyst sentiment is strongly bullish with 78% buy ratings, but investors should monitor execution against elevated expectations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Lam Research Corporation
Lam Research manufactures equipment used to fabricate semiconductors. The firm is focused on the etching, deposition, and clean markets, which are key steps in the semiconductor manufacturing process, especially for 3D NAND flash storage, advanced DRAM, and leading-edge logic/foundry chipmakers. Lam's flagship Kiyo, Vector, and Sabre products are sold in all major geographies to key customers such as Samsung Electronics, Micron, Intel, and Taiwan Semiconductor Manufacturing.
Read more on LRCX →
